Allo-HCT MUD for Non-malignant Red Blood Cell (RBC) Disorders: Sickle Cell, Thal, and DBA: Reduced Intensity Conditioning, Co-tx MSCs
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00957931|
Recruitment Status : Completed
First Posted : August 13, 2009
Results First Posted : August 6, 2018
Last Update Posted : August 6, 2018
The main purpose of this project is to cure patients with high risk Sickle cell disease and other red cell disorders including thalassemia and diamond-blackfan anemia by bone marrow transplantation. The patients enrolled in this study will be those who lack matched sibling donors and therefore have no other option but to undergo bone marrow transplantation using matched but unrelated bone marrow or umbilical cord blood from the national marrow donor program registry. Since bone marrow transplantation for these disorders using matched unrelated donors has two major problems i.e. engraftment, or , the process of new marrow being accepted and allowed to grow in the the patient; and graft-versus-host disease, or the process where the new marrow "rejects" the host or the patient, this study has been devised with methods to overcome these two problems and thus make transplantation from unrelated donors both successful in terms of engraftment and safe in terms of side effects, both acute and long term.
In order to accomplish these two goals, two important things will be done. Firstly, patients will get three medicines which are considered reduced intensity because they are not known to cause the serious organ damage seen with conventional chemotherapy. These medicines, however, do cause intense immune suppression so these can cause increased infections. Secondly, in addition to transplantation of bone marrow from unrelated donors, patients will also transplanted with mesenchymal stromal cells derived from the bone marrow of their parents. Mesenchymal stromal cells are adult stem cells that are normally found in the bone marrow and are thought to create the right background for the blood cells to grow. They have been shown in many animal and human studies to improve engraftment. In addition, they have a special property by which they prevent and are now even considered to treat graft versus host disease. Therefore, by using a reduced intensity chemotherapy regimen before transplant and transplanting mesenchymal stromal cells, we hope to improve engraftment while at the same time decrease the potential for severe side effects associated with a conventional transplant which uses extremely high doses of chemotherapy.
|Condition or disease||Intervention/treatment||Phase|
|Sickle Cell Disease Thalassemia Diamond-Blackfan Anemia||Procedure: Bone marrow transplantation Biological: Mesenchymal Stromal Cells||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||6 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Pilot Study MUD HCT:Pts High Risk Sickle Cell,Other Non-Malignant RBC Disorders- Reduced Intensity Preparative Regimen, HAPLO-Identical Mesenchymal Stromal Cells|
|Actual Study Start Date :||March 2009|
|Actual Primary Completion Date :||August 2013|
|Actual Study Completion Date :||August 2013|
|Experimental: Mesenchymal stromal cells||
Procedure: Bone marrow transplantation
Bone marrow transplantation using matched unrelated donors, reduced intensity conditioning regimen, and co-transplanting mesenchymal stromal cells derived from parental bone marrow.
Biological: Mesenchymal Stromal Cells
- Count of Participants With Stable Engraftment Post Hematopoietic Cell Transplantation (HCT) [ Time Frame: Up to 1 year ]Stable engraftment was defined as absolute neutrophil count (ANC) >500 cells /µL for 3 consecutive days and platelet count >50,000 for one week without transfusion; subsequently stable engraftment was measured by percentage of donor cells.
- Overall Survival 6 Months Following HCT [ Time Frame: 6 months ]Overall survival is reported at the count of participants alive 6 months following HCT.
- Overall Survival 1 Year Following HCT [ Time Frame: 1 year ]Overall survival is reported at the count of participants alive 1 year following HCT.
- Count of Participants With Disease-free Survival 6 Months Following HCT [ Time Frame: 6 months ]Disease-free survival is defined as alive without underlying disease.
- Count of Participants With Disease-free Survival 1 Year Following HCT [ Time Frame: 1 year ]Disease-free survival is defined as alive without underlying disease.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00957931
|United States, Alabama|
|Children's Hospital of Alabama|
|Birmingham, Alabama, United States, 35233|
|United States, Minnesota|
|University of Minnesota|
|Minneapolis, Minnesota, United States, 55455|
|Principal Investigator:||Sandhya Kharbanda, M.D.||Stanford University|